However, pharmacological suppression of TNF-α is not used regularly in patients with SLE (Aringer et al., 2012) despite several small studies demonstrating a significant improvement in disease activity scores (SLEDAI) with anti-TNF-α therapy (Zhu et al., 2010). This evidence concerns the gene TNF and systemic lupus erythematosus.